Yusimry
Yusimry ingredients
| Active ingredient | Strength |
|---|---|
| Adalimumab | 40 mg/.8mL, 40 mg/.4mL, 80 mg/.8mL |
What Yusimry is used for
The FDA lists the approved uses on the official label (below). In the EU, adalimumab is approved as Humira for:
Please refer to the product information document.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Yusimry
- Generic name
- Adalimumab-aqvh
- Made by
- Coherus BioSciences Inc
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- Tumor Necrosis Factor Blocker
- FDA approval
- Biologic licence (BLA) BLA761216
- On the US market since
- 2023
Official information
- Yusimry prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Adalimumab-aqvh)
In India
- Adalimumab: 15 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Yusimry?
Yusimry (Adalimumab-aqvh) is a specialist medicine made by Coherus BioSciences Inc, approved by the US FDA.
What are the ingredients of Yusimry?
Yusimry contains Adalimumab (40 mg/.8mL, 40 mg/.4mL, 80 mg/.8mL).
Is Yusimry approved in Europe?
The same active substance is approved in the EU as Humira.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA